“Our team has demonstrated the presence of SETDB1 abnormalities, particularly its amplification, through WES analysis of osteosarcoma human samples and cell lines” “Our team has demonstrated the ...
NEW YORK--(BUSINESS WIRE)-- OS Therapies (OSTX) (“OS Therapies” or “the Company”), a clinical-stage immunotherapy and Antibody Drug Conjugate (ADC) biopharmaceutical company, today announced the ...
Detecting whether osteosarcoma, a rare but aggressive bone cancer that most often affects children and adolescents, has ...
Osteosarcoma is the bone tumor that most commonly affects children, adolescents, and young adults. Before 1970, treatment primarily included surgical resection. However, the introduction of ...
(RTTNews) - OS Therapies, Inc. (OSTX), a clinical-stage biopharma company specializing in immunotherapies and antibody-drug conjugates, has launched a new subsidiary, OS Animal Health, Inc., to lead ...
(RTTNews) - GSK plc (GSK), a pharmaceutical and biotechnology company, on Tuesday announced that the U.S. Food and Drug Administration or FDA has granted Breakthrough Therapy Designation for GSK'227, ...
NEW YORK--(BUSINESS WIRE)--OS Therapies (NYSE-A: OSTX) (“OS Therapies” or “the Company”), a clinical-stage immunotherapy and Antibody Drug Conjugate (ADC) biopharmaceutical company, today announced ...
Yet to be published data from clinical study combining OST-HER2 with palliative radiation in dogs with unresected, primary osteosarcoma shows clinical and radiographic arrest of the primary tumor, ...
Chimeric antigen receptor (CAR) T–cell immunotherapy re-engineers a patient's immune cells to target cancer cells. While successful in some types of leukemia, the approach has yet to realize its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results